On the evening of March 31, Huaren Pharmaceutical Co.Ltd(300110) released the annual report for 2021. The company’s overall performance improved significantly, realizing an operating revenue of 1.561 billion yuan and a net profit attributable to shareholders of listed companies of 130 million yuan, with a year-on-year increase of 18.55% and 37.81% respectively.
business transformation effect initially achieved performance commitment
In 2021, in the face of continuous and repeated outbreaks outside China, complex and changeable macroeconomic situation, pressure and challenges such as pharmaceutical industry reform and national centralized drug purchase, Huaren Pharmaceutical Co.Ltd(300110) closely focused on the strategic goal of “pharmaceutical health”, actively responded to industry changes and accelerated business transformation.
In November 2020, Huaren Pharmaceutical Co.Ltd(300110) acquired Guangxi Yuyuan Pharmaceutical Co., Ltd. to quickly supplement the company’s large infusion varieties and product specifications. In August 2021, it acquired 100% equity of Xi’an hengjuxing Pharmaceutical Co., Ltd. and Anhui Xingxing Pharmaceutical Co., Ltd. Promote the innovation, upgrading and rapid development of Huaren Pharmaceutical Co.Ltd(300110) in the construction of R & D platform, expand the business field from large infusion and nephrology to respiratory and fine Anesthesiology, expand the drug dosage form from large capacity to small capacity injection, tablet, capsule, powder, granule and other dosage forms, further improve the variety and dosage form, promote the integrated development of “raw material + Preparation”, and constantly expand the growth space and thickness of the enterprise.
In 2021, Huaren Pharmaceutical Co.Ltd(300110) strengthened the M & A and integration of Guangxi Yuyuan pharmaceutical and Anhui Xingxing pharmaceutical, accelerated the integration from the aspects of manpower, finance, internal control and business, strengthened the standardized operation and compliance operation, and gave full play to the synergy. Channel integration of the company’s original products with Yuyuan and Xingxing products has been carried out, market access and national network connection have been accelerated, resources have been fully integrated and complementary advantages have been realized. Both subsidiaries have fulfilled their performance commitments for the year and contributed some profits.
In 2021, Huaren Pharmaceutical Co.Ltd(300110) takes the construction of product strength as the core and the national centralized purchase varieties and consistency evaluation varieties as the key direction to promote the development of new drugs with high added value and high technical barriers, further enrich the R & D pipeline, expand and cultivate new forces. Through the acquisition of Anhui Xingxing pharmaceutical, the company has newly obtained 17 drug varieties such as doxofylline injection, compound potassium hydrogen phosphate injection, fasudil hydrochloride injection, diquine ammonium chloride buccal tablets and caffeine citrate injection, as well as 8 API varieties such as doxofylline, pentazocine and lecardi hydrochloride. Among them, doxofylline injection has passed the consistency evaluation and won the bid for the centralized procurement of the fourth batch of national drugs. By the end of 2021, Huaren Pharmaceutical Co.Ltd(300110) had invested 671045 million yuan in R & D, an increase of 21.53% over the same period of last year. At present, 33 varieties have entered the national medical insurance catalogue. In 2021, two varieties of citicoline sodium chloride injection and isosorbide nitrate sodium chloride injection were newly included in the 2021 edition of the national medical insurance catalogue.
accelerate marketing transformation and enable endogenous growth
In 2021, Huaren Pharmaceutical Co.Ltd(300110) seize the opportunity of industry reform, actively promote marketing transformation, accelerate the construction of core products, core customers and core teams, and meet a new round of pharmaceutical system reform and industry development cycle with new ideas, new methods and new features. Further strengthen market access, actively participate in national, provincial and prefecture level centralized mining, do a good job in the channel layout of non centralized mining market, and constantly explore incremental markets. With the effective control of the epidemic situation in China, the sales of self-produced drugs of the company have increased steadily. In 2021, the company sold 388 million bottles (bags / bottle) of drugs as a whole, an increase of 102.15% over the same period of last year. At the same time, the company actively promoted the layout of the whole pharmaceutical and health industry chain and expanded pharmaceutical business. The pharmaceutical business sector grew steadily and contributed some profits.
In the future, Huaren Pharmaceutical Co.Ltd(300110) will firmly focus on the strategic goal of “great health of medicine”, focus on the construction of core products, core teams and core customers, steadily promote business transformation, accelerate the development of new drugs, promote the construction and upgrading of product power, coordinate the construction of base, accelerate digital transformation, establish the low-cost advantage of the whole industrial chain, strengthen capital operation, promote compliance development, and strive to grow into a company with fine Anesthesiology, respiratory, Nephrology It is a pharmaceutical and health industry group with therapeutic high-volume preparations, medical devices and other products as the main line, basic infusion and large health products as the two wings, the integration of research, production and marketing, and the comprehensive and coordinated development of APIs, preparations, medical devices, medical packaging materials and other sectors.
